16:06 EST Rigel Pharmaceuticals (RIGL) sees FY26 revenue $275M-$290M, consensus $279.31M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20
- Is RIGL a Buy, Before Earnings?
- Rigel Pharmaceuticals Appoints Michael P. Miller to Board
- Rigel Pharmaceuticals price target raised to $71 from $69 at Citi
- Rigel: Strengthening Commercial Trajectory, Clear Path to 2026 Profitability, and Advancing Pipeline Support Buy Rating